Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Robertson

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Journal of Neuroinflammation|June 24, 2016
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsLewis M Watkins, James W Neal, Sam Loveless, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 17, 2012
Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxiaEsther B E Becker, Luigi Zuliani, Rosemary Pettingill, et al.
Human Brain Mapping|March 21, 2019
Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosisIlona Lipp, Derek K Jones, Sonya Bells, et al.
European Journal of Neurology|February 9, 2026
MOGAD in South Wales: Diagnostic Evolution and Disease EpidemiologySophie Voase, Patrick Waters, Stephen Jolles, et al.
The Lancet. Neurology|April 6, 2015
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparatorJacqueline Palace, Martin Duddy, Thomas Bregenzer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 17, 2012
Long-term outcome of paediatric-onset multiple sclerosis: a population-based studyKatharine E Harding, Kate Liang, Mark D Cossburn, et al.
Journal of the Neurological Sciences|August 12, 2020
Serum neurofilament-light concentration and real-world outcome in MSValerie Anderson, Emily Bentley, Sam Loveless, et al.
Brain Pathology (Zurich, Switzerland)|July 15, 2017
Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosisSam Loveless, James W Neal, Owain W Howell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 5, 2018
How common is truly benign MS in a UK population?Emma Clare Tallantyre, Paula C Major, Michael J Atherton, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Journal of Neuroinflammation|June 24, 2016
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsLewis M Watkins, James W Neal, Sam Loveless, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 17, 2012
Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxiaEsther B E Becker, Luigi Zuliani, Rosemary Pettingill, et al.
Human Brain Mapping|March 21, 2019
Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosisIlona Lipp, Derek K Jones, Sonya Bells, et al.
European Journal of Neurology|February 9, 2026
MOGAD in South Wales: Diagnostic Evolution and Disease EpidemiologySophie Voase, Patrick Waters, Stephen Jolles, et al.
The Lancet. Neurology|April 6, 2015
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparatorJacqueline Palace, Martin Duddy, Thomas Bregenzer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 17, 2012
Long-term outcome of paediatric-onset multiple sclerosis: a population-based studyKatharine E Harding, Kate Liang, Mark D Cossburn, et al.
Journal of the Neurological Sciences|August 12, 2020
Serum neurofilament-light concentration and real-world outcome in MSValerie Anderson, Emily Bentley, Sam Loveless, et al.
Brain Pathology (Zurich, Switzerland)|July 15, 2017
Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosisSam Loveless, James W Neal, Owain W Howell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 5, 2018
How common is truly benign MS in a UK population?Emma Clare Tallantyre, Paula C Major, Michael J Atherton, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Pageof 13